Gene Therapy - Neurturin - Phase II

Study Title:

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

This Phase 2 clinical study delivers neurturin (NTN), a protein related to glial cell line-derived neurotrophic factor (GDNF), to both the putamen and substantia nigra. Patients are randomized to either the treatment versus sham surgery. 


  1. Moderate to advanced Parkinson's disease
  2. Both sides affected, classic PD with motor fluctuations
  3. Good postural stability in the “on” state
  4. Age 35-70 years
  5. Normal cognitive status


Robin Taylor

[email protected]

(415) 353-1555

For more information, please visit the study page at, here